Co-Authors
This is a "connection" page, showing publications co-authored by MARINA KONOPLEVA and BING Z CARTER.
Connection Strength
1.479
-
Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells. Mol Cancer Ther. 2022 06 01; 21(6):879-889.
Score: 0.211
-
Beyond BCL-2 Inhibition in Acute Myloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway. Clin Lymphoma Myeloma Leuk. 2022 09; 22(9):652-658.
Score: 0.209
-
Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 15; 24(10):2417-2429.
Score: 0.157
-
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016 09 07; 8(355):355ra117.
Score: 0.142
-
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 2015 Oct 13; 6(31):30487-99.
Score: 0.133
-
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood. 2012 Jul 05; 120(1):173-80.
Score: 0.106
-
XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis. 2011 Jan; 16(1):67-74.
Score: 0.096
-
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther. 2009 Sep; 8(9):2509-16.
Score: 0.087
-
Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle. 2006 Oct; 5(19):2223-9.
Score: 0.071
-
Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv. 2023 12; 9(48):eadh1436.
Score: 0.059
-
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica. 2022 06 01; 107(6):1311-1322.
Score: 0.053
-
Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML. Transl Oncol. 2022 Apr; 18:101354.
Score: 0.052
-
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.
Score: 0.050
-
Apoptosis in leukemias: regulation and therapeutic targeting. Cancer Treat Res. 2010; 145:197-217.
Score: 0.022
-
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood. 2007 Mar 01; 109(5):2121-9.
Score: 0.018
-
Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood. 2002 May 01; 99(9):3461-4.
Score: 0.013